Table 2 Logistic regression analysis of the risk factors for VTE in the training set

Age (Mean ± SD)

64.1 ± 10.2

63.4 ± 10.3

0.99 (0.97–1.01, p = .568)

Sex

 Female

670 (29.3%)

39 (43.8%)

 Male

1620 (70.7%)

50 (56.2%)

0.53 (0.35–0.81, p = .004)

KPS (Mean ± SD)

76.5 ± 11.5

78.3 ± 9.0

1.01 (0.99–1.04, p = .160)

1.02 (1.00–1.05, p = .048)

Stage of cancer

 I–II

304 (13.3%)

2 (2.2%)

 III

515 (22.5%)

8 (9%)

2.36 (0.50–11.19, p = .279)

2.38 (0.48–11.73, p = .287)

 IV

1471 (64.2%)

79 (88.8%)

8.16 (2.00–33.39, p = .004)

6.23 (1.43–27.25, p = .015)

Pathological type

 NSCLC

1996 (87.2%)

85 (95.5%)

 SCLC

294 (12.8%)

4 (4.5%)

0.32 (0.12–0.88, p = .027)

Varicosity

 No

2282 (99.7%)

84 (94.4%)

 Yes

8 (0.3%)

5 (5.6%)

16.98 (5.44–53.00, p < .001)

18.68 (4.10–85.10, p < .001)

COPD

 No

1845 (80.6%)

61 (68.5%)

 Yes

445 (19.4%)

28 (31.5%)

1.90 (1.20–3.01, p = .006)

2.26 (1.36–3.76, p = .002)

CVC

 No

2227 (97.2%)

80 (89.9%)

 Yes

63 (2.8%)

9 (10.1%)

3.98 (1.91–8.28, p < .001)

2.28 (0.99–5.25, p = .053)

History of malignant tumor

 No

2256 (98.5%)

89 (100%)

 Yes

34 (1.5%)

0 (0%)

0.00 (0.00-Inf, p = .974)

BMI

 < 18.5

203 (8.9%)

6 (6.7%)

 18.5–23.9

1266 (55.3%)

39 (43.8%)

1.04 (0.44–2.49, p = .926)

0.82 (0.32–2.06, p = .666)

 ≥ 24

821 (35.9%)

44 (49.4%)

1.81 (0.76–4.31, p = .178)

1.39 (0.55–3.53, p = .492)

PLT (Mean ± SD)

222.9 ± 100.0

211.3 ± 87.0

1.00 (1.00–1.00, p = .283)

Albumin (Mean ± SD)

38.8 ± 6.3

37.6 ± 6.9

0.97 (0.94–1.00, p = .078)

0.95 (0.91–0.98, p = .006)

D dimer (Mean ± SD)

2.1 ± 3.7

2.6 ± 4.0

1.03 (0.99–1.08, p = .186)

PT (Mean ± SD)

12.0 ± 1.8

11.5 ± 2.1

0.76 (0.64–0.91, p = .002)

0.79 (0.65–0.95, p = .015)

APTT (Mean ± SD)

28.6 ± 5.8

27.5 ± 5.5

0.96 (0.92–1.00, p = .080)

Hemoglobin (Mean ± SD)

122.0 ± 20.7

117.7 ± 19.5

0.99 (0.98–1.00, p = .052)

Leukocyte (Mean ± SD)

5.6 ± 5.3

7.1 ± 6.3

1.04 (1.01–1.08, p = .010)

1.05 (1.01–1.09, p = .006)

Creatinine (Mean ± SD)

66.8 ± 36.7

61.7 ± 20.2

0.99 (0.98–1.00, p = .120)

Mitomycin

 No

2285 (99.8%)

89 (100%)

 Yes

5 (0.2%)

0 (0%)

0.00 (0.00-Inf, p = .985)

rh-Endostatin

 No

2223 (97.1%)

86 (96.6%)

 Yes

67 (2.9%)

3 (3.4%)

1.16 (0.36–3.75, p = .808)

EGFR-TKI

 No

2044 (89.3%)

45 (50.6%)

 Yes

246 (10.7%)

44 (49.4%)

8.12 (5.25–12.57, p < .001)

4.71 (2.90–7.67, p < .001)

Dexamethasone

 No

614 (26.8%)

5 (5.6%)

 Yes

1676 (73.2%)

84 (94.4%)

6.15 (2.49–15.24, p < .001)

3.88 (1.52–9.95, p = .005)

Platinum

 No

1868 (81.6%)

61 (68.5%)

 Yes

422 (18.4%)

28 (31.5%)

2.03 (1.28–3.22, p = .002)

Bevacizumab

 No

2247 (98.1%)

75 (84.3%)

 Yes

43 (1.9%)

14 (15.7%)

9.75 (5.12–18.60, p < .001)

3.14 (1.46–6.77, p = .003)